Research Paper Volume 11, Issue 21 pp 9875—9892

Promising therapeutic effect of thapsigargin nanoparticles on chronic kidney disease through the activation of Nrf2 and FoxO1

Figure 5. The roles of FoxO1 and Nrf2 after TG NP treatment in HK-2 cells. (A) The protein levels of FoxO1 and Nrf2 in the cytoplasmic and nuclear fractions of HK-2 cells treated with TG NPs are shown. p84 and GAPDH served as loading controls for the nuclear and cytoplasmic fractions, respectively. Cells were treated with different concentrations of the TG NPs for 24 h. Western blotting showed the efficiency of the siRNA-mediated knockdown of FoxO1 (B) and Nrf2 (C) expression. (D) The effects of FoxO1 or Nrf2 siRNA on cell viability were tested. Cells were transfected with a control, FoxO1-specific or Nrf2-specific siRNA for 24 h, treated with TG NPs (200 nM) for 6 h and then incubated with H2O2 (500 μM) for 18 h. *p < 0.05, H2O2+control siRNA versus H2O2+TG NPs + control siRNA. #p < 0.05, H2O2+TG NPs + control siRNA versus H2O2+TG NPs+FoxO1 or Nrf2 siRNA.